Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers

Aurobindo Pharma Q4FY21 consolidated net profit at Rs. 801.58 Cr

The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021

Aurobindo Pharma to acquire 26% ownerships solar power companies

The company will be holding 26% of the share capital in each of the solar power generating companies.

Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities

Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.

Pharma stocks face Q4 reality check amid global headwinds

Analysts expect modest revenue growth but pressure on profitability in the March quarter

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga

CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG

STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories

APL Healthcare’s Unit-IV classified as VAI by the USFDA

This inspection is now closed

Eugia Pharma launches Pomalidomide capsules in US market

Eugia Pharma receives USFDA Approval for Everolimus tablets